NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Cost-Offsets of New Medications for Treatment of Schizophrenia

Richard G. Frank, Thomas G. McGuire, Sharon-Lise Normand

NBER Working Paper No. 12643
Issued in October 2006
NBER Program(s):   HC

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia. We extend research in this area by taking a new approach to identification of spending impacts of new drugs. We specify and estimate models of spending on treatment of schizophrenia using 7 years of Florida Medicaid data. The estimates indicate that use of the new drugs result in net spending increases. This may be due to increased adherence to treatment.

download in pdf format
   (126 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (126 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w12643

Users who downloaded this paper also downloaded these:
Shen w12374 The Effects of HMO and Its For-Profit Expansion on the Survival of Specialized Hospital Services
Lampe and Moser w15061 Do Patent Pools Encourage Innovation? Evidence from the 19th-Century Sewing Machine Industry
Farmer, Zha, and Waggoner w14710 Understanding Markov-Switching Rational Expectations Models
McArdle, Smith, and Willis w15266 Cognition and Economic Outcomes in the Health and Retirement Survey
Fraumeni w14736 The Contribution of Highways to GDP Growth
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us